EP Patent

EP2931707A4 — Enhancer of zeste homolog 2 inhibitors

Assigned to GlaxoSmithKline LLC · Expires 2016-07-20 · 10y expired

What this patent protects

Patent listed against tazemetostat-hydrobromide.

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: EP2931707A4
Jurisdiction: EP
Classification: —
Expires: 2016-07-20
Drug substance claim: No
Drug product claim: No
Assignee: GlaxoSmithKline LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.